SCHEMBL4144971

SCHEMBL4144971

Cc1c(-c2ccc(Cl)c(Cl)c2)[nH]c2ccc3[nH]c(=O)cc(Cl)c3c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HTT P42858 2/20 0.42
IKBKB O14920 1/20 0.41
AR P10275 1/20 0.41
TNKS2 Q9H2K2 4/20 0.41
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
USP2 O75604 1/20 0.40
GAA P10253 1/20 0.40
PKM P14618 1/20 0.40
ALOX12 P18054 1/20 0.40
LMNA P02545 1/20 0.39
PAK4 O96013 1/20 0.38
PRKX P51817 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
PTGES O14684 1/20 0.37
ALOX5 P09917 1/20 0.37
IDO1 P14902 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4143949 0.87 LMNA (0.46) MEN1KMT2AARTNKS2MAPT
SCHEMBL4148107 0.85 HPGD (0.47) MEN1KMT2AHTTARTNKS2
SCHEMBL4146511 0.84 LMNA (0.44) MEN1KMT2AARLMNAPAK4
SCHEMBL4145440 0.84 TNKS2 (0.47) ARTNKS2MAPTLMNACYP1A2
SCHEMBL4140138 0.84 KIF11 (0.44) MEN1KMT2AARTNKS2MAPT
SCHEMBL4146476 0.82 CSNK1D (0.41) MEN1KMT2AHTTARTNKS2
SCHEMBL4140109 0.82 MAOA (0.44) MEN1KMT2AARKDM4EGAA
SCHEMBL4142870 0.81 AR (0.46) MEN1KMT2AARTNKS2MAPT
SCHEMBL4144687 0.80 AR (0.46) ARTNKS2MAPTLMNACYP1A2
SCHEMBL9949807 0.79 MAPK14 (0.55) MEN1KMT2AHTTARMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1891067-B1 ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARM INC (US) 2016-01-13 EP disclosed
US-8580811-B2 Androgen receptor modulator methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2013-11-12 US disclosed
US-20120165362-A1 Androgen receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED 2012-06-28 US disclosed
US-8193357-B2 Androgen receptor modulator compounds LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-06-05 US disclosed
US-20090264455-A9 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-10-22 US disclosed
US-20090030027-A1 Androgen Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030027-A1 Androgen Receptor Modulator Compounds and Methods AR, NR5A1, ESRRA MEN1 3649/4885KMT2A 1929/4885HTT 4734/4885
US-20120165362-A1 Androgen receptor modulator compounds and methods AR, NR5A1, ESRRA MEN1 3649/4885KMT2A 1929/4885HTT 4734/4885
US-20090264455-A9 Androgen Receptor Modulator Compounds and Methods AR, NR5A1, ESRRA MEN1 3649/4885KMT2A 1929/4885HTT 4734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.